Cocrystal Pharma (COCP) Net Margin (2010 - 2026)

Cocrystal Pharma (COCP) reported Net Margin of 1037.33% for Q1 2026, down 249.89% sequentially from 296.47% in Q4 2020.

Cocrystal Pharma (COCP) Net Margin (2010 - 2026) Analysis & Trends

Cocrystal Pharma (COCP) has 8 years of Net Margin data on file, last reported at 1037.33% in Q1 2026.

For the quarter ending Q1 2026, Net Margin changed N/A year-over-year to 1037.33%; the trailing twelve-month figure through Mar 2026 stood at 555.34% (changed N/A YoY), and the FY2020 full-year result was 479.05%, up 25479.0% from the prior year.
Net Margin fell to 1037.33% in Q1 2026, from 296.47% in the prior quarter.
In the past five years, Net Margin ranged from a high of 1037.33% in Q1 2026 to a low of 1037.33% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	15.02%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	20.17%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Cocrystal Pharma	12.57 Mn	7.74 Mn	-	-1,037.33%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-1,037.33%
Dec 31, 2020	-296.47%
Sep 30, 2020	-572.60%
Jun 30, 2020	-749.64%
Mar 31, 2020	-590.02%
Dec 31, 2019	-11,901.74%
Sep 30, 2019	-361.79%
Jun 30, 2019	-255.91%
Mar 31, 2019	58.51%
Sep 30, 2015	-2,550.00%
Jun 30, 2015	-9,329.63%
Mar 31, 2015	-108,618.52%
Jun 30, 2013	-37.31%
Mar 31, 2013	-72.74%
Dec 31, 2012	-11.29%
Sep 30, 2012	0.49%
Jun 30, 2012	-14.54%
Mar 31, 2012	-103.87%
Dec 31, 2011	-50.25%
Sep 30, 2011	-63.60%